Keyphrases
Acute Lymphoblastic Leukemia
55%
Acute Myeloid Leukemia
93%
Ara-C
13%
Bortezomib
13%
Cancer Treatment
11%
Chemotherapy
25%
Childhood Acute Lymphoblastic Leukemia
63%
Childhood Cancer
29%
Childhood Cancer Patients
15%
Childhood Cancer Survivors
26%
Childhood Cancer Treatment
15%
Childhood Leukemia
12%
Children with Cancer
29%
Complete Remission
10%
Cytarabine
18%
Diffuse Intrinsic Pontine Glioma
43%
Doxorubicin
10%
Drug Resistance
24%
Dutch
33%
Event-free Survival
17%
Health-related Quality of Life
10%
Healthcare Professionals
17%
Healthcare Provider Perspectives
11%
Indonesia
16%
Kenya
19%
L-asparaginase
12%
Late Effects
10%
Leukemia
16%
Leukemia Patients
17%
Methotrexate
15%
Netherlands
11%
Newly Diagnosed
11%
Oncology
12%
Overall Survival
19%
Pediatric
39%
Pediatric Acute Lymphoblastic Leukemia
19%
Pediatric Leukemia
84%
Pediatric Oncology
14%
Pediatric Patients
13%
Prednisolone
15%
Prognostic Significance
10%
Protease Inhibitors
11%
Quality of Life
16%
Randomized Controlled Trial
11%
Relapsed or Refractory Acute Myeloid Leukemia
23%
Survivors
14%
Treatment Outcome
13%
Tumor
16%
Vincristine-induced Peripheral Neuropathy
10%
Working Diagnosis
16%
Medicine and Dentistry
Acute Leukemia
12%
Acute Lymphoblastic Leukemia
62%
Acute Myelogenous Leukemia
18%
Acute Myeloid Leukemia
100%
Adolescence
12%
Bortezomib
9%
Cancer
8%
Cancer Therapy
18%
Chemotherapy
39%
Childhood Cancer
74%
Childhood Leukemia
7%
Clinical Trial
11%
Complementary and Alternative Medicine
8%
Cytarabine
12%
Diagnosis
9%
Disease
23%
Drug Resistance
13%
Event Free Survival
19%
Ganglioglioma
7%
Ganglioneuroblastoma
10%
Glomerular Filtration Rate
6%
Hazard Ratio
6%
Health Care Provider
12%
High Risk Population
7%
In Vitro
18%
Leukemia
18%
Leukemia Cell
11%
Liposomal Daunorubicin
9%
Low and Middle Income Countries
7%
Malignant Neoplasm
40%
Minimal Residual Disease
9%
Neoplasm
19%
Oncology
8%
Overall Survival
25%
Pediatric Acute Myeloid Leukemia
64%
Pediatrics
59%
Pediatrics Patient
11%
Pontine Glioma
27%
Prognostic Factor
9%
Proteasome
8%
Proteasome Inhibitor
10%
Quality of Life
13%
Radiation Therapy
12%
Randomized Controlled Trial
8%
Retrospective Study
9%
Supportive Care
8%
Survival Rate
11%
Systematic Review
10%
Vincristine
11%
Wilms' Tumor
7%